



Universiteit  
Leiden  
The Netherlands

## Identification and treatment of patients at high cardiovascular risk

Zijlstra, L.E.

### Citation

Zijlstra, L. E. (2021, September 16). *Identification and treatment of patients at high cardiovascular risk*. Retrieved from <https://hdl.handle.net/1887/3210403>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3210403>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3210403> holds various files of this Leiden University dissertation.

**Author:** Zijlstra, L.E.

**Title:** Identification and treatment of patients at high cardiovascular risk

**Issue Date:** 2021-09-16

# **IDENTIFICATION AND TREATMENT OF PATIENTS AT HIGH CARDIOVASCULAR RISK**

**LAURIEN E. ZIJLSTRA**

# COLOPHON

Cover and lay-out: Thomas Houwers

Illustrations: Iris le Rütte | [www.irislerutte.nl](http://www.irislerutte.nl)

Printed by: ProefschriftMaken, De Bilt | [www.proefschriftmaken.nl](http://www.proefschriftmaken.nl)

ISBN: 978-94-6423-374-2

The studies described in this thesis were conducted at the Department of Cardiology of the Leiden University Medical Center, Leiden, The Netherlands

Financial support for this thesis by Pfizer and Boehringer Ingelheim BV is gratefully acknowledged.

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.

© 2021 Laurien E. Zijlstra, Leiden, The Netherlands. All rights reserved. No part of this book may be reproduced or transmitted, in any form or by any means, without prior permission of the author.

# **IDENTIFICATION AND TREATMENT OF PATIENTS AT HIGH CARDIOVASCULAR RISK**

## **PROEFSCHRIFT**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. dr. ir. H. Bijl,  
volgens het besluit van het college voor promoties  
te verdedigen op donderdag 16 september 2021  
klokke 16:15 uur

door

**LAURIEN ERMINE ZIJLSTRA**

geboren te Zwolle  
in 1992

**PROMOTOR:**

Prof. dr. J.W. Jukema

**CO-PROMOTORES:**

Dr. S. Trompet

Dr. S.P. Mooijaart

**LEDEN PROMOTIECOMMISSIE:**

Prof. dr. J. Gussekloo, secretaris

Dr. M. van Buren (Leids Universitair Medisch Centrum en HagaZiekenhuis)

Prof. dr. S.A.J. Chamuleau (Amsterdam Universitair Medisch Centrum)

Prof. Dr. D.E. Atsma

Prof. Dr S.C. Cannegieter

Prof. Dr. P.H.A. Quax



# THESIS OUTLINE

<b>1</b>	<b>GENERAL INTRODUCTION, AIM AND OUTLINE OF THE THESIS.</b>	<b>8</b>
<b>PART 1. IDENTIFICATION OF HIGH-RISK CARDIOVASCULAR PATIENTS</b>		
<b>2</b>	<b>MICROVASCULAR DISEASE IN WOMEN AND MEN.</b> Zijlstra LE, Bootsma M, Jukema JW, Schaliij MJ, Vliegen HW and Brusckhe AVG. Chest pain in the absence of obstructive coronary artery disease. A critical review of current concepts focusing on sex specificity, microcirculatory function, and clinical implications. <i>Int J Cardiol.</i> 2019;280:19-28.	<b>20</b>
<b>3</b>	<b>CR1 POLYMORPHISM AND COGNITION IN OLDER PATIENTS WITH VASCULAR DISEASE.</b> Zijlstra LE, Jukema JW, Mooijaart SP, de Vries MA, Stott DJ, Castro Cabezas M and Trompet S. Association of complement receptor 1 gene polymorphisms with cognitive function. <i>Physiol Genomics.</i> 2018;50(2):102-3.	<b>62</b>
<b>4</b>	<b>CARDIOVASCULAR STRUCTURE AND FUNCTION AND CEREBROVASCULAR CHANGES AND COGNITIVE FUNCTION IN OLDER PATIENTS REACHING END-STAGE RENAL DISEASE.</b> Zijlstra LE, Trompet S, Jukema JW, Kroft LJM, de Bresser J, van Osch MJP, Hammer S, Witjes M-N, van Buren M and Mooijaart SP. Association of Cardiac Parameters with Cerebrovascular Changes and Cognitive Function in Older Patients with End-Stage Renal Disease. <i>Aging.</i> 2020; 12 (2): 1496-1511.	<b>76</b>
<b>5</b>	<b>KIDNEY FUNCTION AND COGNITIVE DECLINE IN OLDER PATIENTS WITH VASCULAR DISEASE.</b> Zijlstra LE, Trompet S, Mooijaart SP, van Buren M, Sattar N, Stott DJ and Jukema JW. Association of kidney function and cognitive decline in older patients at risk of cardiovascular disease. <i>BMC Nephrology.</i> 2020; 21 (1): 81.	<b>104</b>
<b>6</b>	<b>KIDNEY FUNCTION, SUBCLINICAL THYROID DISEASE AND CARDIOVASCULAR OUTCOMES IN OLDER PATIENTS WITH VASCULAR DISEASE.</b> Zijlstra LE, van Velzen DM, Simsek S, Mooijaart SP, van Buren M, Stott DJ, Ford I, Jukema JW and Trompet S. The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients. <i>Endocrine Connections.</i> 2020; 9 (1): 55-62.	<b>128</b>
<b>PART 2. TREATMENT OF HIGH-RISK CARDIOVASCULAR PATIENTS</b>		
<b>7</b>	<b>PCSK9 INHIBITION IN POLYVASCULAR DISEASE.</b> Jukema JW and Szarek M (shared first authors), Zijlstra LE (second author), de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG and Steg PG. Post-Acute Coronary Syndrome Patients With Polyvascular Disease Derive Large Absolute Benefit From Alirocumab: ODYSSEY OUTCOMES. <i>J Am Coll Cardiol.</i> 2019; 74(9): 1167-1176. Editorial: <i>Genest J et al. 2019; 74 (9): 1187-1189</i> Letter to the editor: <i>Alkhalil M. 2020; 75 (2): 240-241</i> Reply to letter: <i>Zijlstra LE, Schwartz GG, Steg PG and Jukema JW. Reply to Alirocumab in Polyvascular Atherosclerotic Disease. J Am Coll Cardiol. 2020; 75 (2): 241.</i>	<b>152</b>

<b>8</b>	<b><i>PCSK9 INHIBITION AND STROKE.</i></b>	<b>184</b>
	Zijlstra LE and Jukema JW (shared first authors), Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim Y-U, Pordy R, Reiner Ž, Roe MT, Tse H-F, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> . 2019; 140 (25): 2052-2062. Editorial: <i>Michos et al. 2019; 140 (25): 2063-2066</i>	
<b>9</b>	<b><i>PCSK9 INHIBITION IN KIDNEY DISEASE.</i></b>	<b>212</b>
	Zijlstra LE, Trompet S, Mooijaart SP, van Buren M and Jukema JW. Editorial: Renal impairment, cardio-vascular disease and the short term efficacy and safety of PCSK9 targeted by inclisiran. <i>Mayo Clinic Proceedings</i> . 2020; 95 (1): 9-11.	
<b>10</b>	<b><i>PCSK9 INHIBITION IN PATIENTS AT HIGH CARDIOVASCULAR RISK.</i></b>	<b>220</b>
	Zijlstra LE, Mooijaart SP and Jukema JW. Editorial: PCSK9 inhibition in the high-risk patient. <i>Aging</i> . 2019; 11 (23): 10791-10792.	
<b>11</b>	<b><i>LEVOTHYROXINE TREATMENT AND CARDIOVASCULAR OUTCOMES IN OLDER PEOPLE WITH SUBCLINICAL HYPOTHYROIDISM.</i></b>	<b>226</b>
	Zijlstra LE, Jukema JW, Westendorp RGJ, Du Puy RS, Poortvliet RKE, Kearney PM, O’Keeffe L, Dekkers OM, Blum MR, Rodondi N, Collet TH, Quinn TJ, Sattar N, Stott DJ, Trompet S, den Elzen WPJ, Gussekloo J and Mooijaart SP. Levothyroxine Treatment and Cardiovascular Outcomes in Older People with Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials. <i>Frontiers in Endocrinology</i> . Accepted.	
<b>12</b>	<b><i>SUMMARY AND PERSPECTIVES.</i></b>	<b>244</b>
<b>13</b>	<b><i>NEDERLANDSE SAMENVATTING.</i></b>	<b>258</b>
	<i>LIST OF PUBLICATIONS.</i>	<b>270</b>
	<i>LIST OF ABBREVIATIONS.</i>	<b>272</b>
	<i>LIST OF CONTRIBUTING AUTHORS.</i>	<b>274</b>
	<i>DANKWOORD.</i>	<b>278</b>
	<i>CURRICULUM VITAE.</i>	<b>279</b>